Ocular Immunovirology Service, Department of Sense Organs, Sapienza University of Rome, Rome, Italy.
Ocul Immunol Inflamm. 2022 Jul;30(5):1228-1233. doi: 10.1080/09273948.2022.2027469. Epub 2022 Feb 24.
To report a relapse of Vogt-Koyanagi-Harada (VKH) disease in a patient after COVID-19 vaccination.
A VKH disease patient, well controlled on azathioprine therapy, presented a uveitis relapse eleven days after the first vaccination for COVID-19. She received an induction high-dose intravenous corticosteroid therapy, followed by oral therapy, which led to a complete recovery from the uveitis in two weeks. No relapses occurred in the following five months of follow-up. Despite high-dose corticosteroid therapy and azathioprine, and one dose only of vaccination, the patient resulted positive for anti-RBD spike COV19 antibody.
Relapse of VKH disease can occur after COVID-19 vaccination, despite an appropriate immunosuppressive therapy is ongoing. It responds to the classic therapy for VKH, and a serological response to an incomplete COVID-19 vaccination can also be found.
报告一例 COVID-19 疫苗接种后 Vogt-小柳原田（VKH）病复发。
一名 VKH 病患者，在用硫唑嘌呤治疗得到良好控制后，在 COVID-19 首次接种疫苗后 11 天出现葡萄膜炎复发。她接受了诱导高剂量静脉注射皮质类固醇治疗，随后进行了口服治疗，两周内葡萄膜炎完全恢复。在随后的五个月随访中没有复发。尽管进行了高剂量皮质类固醇治疗和硫唑嘌呤治疗，并且仅接种了一剂疫苗，但患者的抗 RBD 刺突 COV19 抗体呈阳性。
尽管正在进行适当的免疫抑制治疗，但 COVID-19 疫苗接种后仍可能发生 VKH 病复发。它对 VKH 的经典治疗有反应，也可以发现对不完全 COVID-19 疫苗接种的血清学反应。
